Business
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that management will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that management will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.","length":361,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Lipocine Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Lipocine Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":113,"url":"https://media.zenfs.com/en/prnewswire.com/62a81ae3d468802b850c2f8f9ddf2cd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B1SDSAYJo_O_iHxhnnxqJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5OQ--/https://media.zenfs.com/en/prnewswire.com/62a81ae3d468802b850c2f8f9ddf2cd2","width":400,"height":113},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/v8xe9UjIyrNyEUzIgHW5GA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE4MQ--/https://media.zenfs.com/en/prnewswire.com/62a81ae3d468802b850c2f8f9ddf2cd2","width":400,"height":113}},"href":"https://mma.prnewswire.com/media/627654/Lipocine_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Fireside Chat Details:","length":22,"tagName":"p"},{"type":"text","content":"Time: 3:00 PM ET","length":16,"tagName":"p"},{"type":"text","content":"Date: Wednesday, May 20, 2026","length":29,"tagName":"p"},{"type":"text","content":"Investors can register for the conference and view the fireside chat here.","length":74,"tagName":"p"},{"type":"text","content":"About Lipocine","length":14,"tagName":"p"},{"type":"text","content":"Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.","length":473,"tagName":"p"},{"type":"text","content":"Lipocine's development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disord...